Catalyst Pharmaceuticals (CPRX) Change in Account Payables (2010 - 2026)

Catalyst Pharmaceuticals' Change in Account Payables history runs 17 years deep, the most recent figure standing at -$4.1 million for Q1 2026.

• Quarterly Change in Account Payables rose 24.93% year-over-year to -$4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.0 million (down 532.26% YoY) and the FY2025 annual result came in at -$5.4 million, down 399.83% from the prior year.
• Change in Account Payables was -$4.1 million for Q1 2026 at Catalyst Pharmaceuticals, down from $2.1 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $10.2 million in Q4 2023 and bottomed at -$5.7 million in Q2 2025.
• A 5-year average of $257823.5 and a median of $214000.0 in 2022 frame the typical range for Change in Account Payables.
• Peak annual rise in Change in Account Payables reached 8937.5% in 2022, while the deepest fall reached 873.7% in 2022.
• Catalyst Pharmaceuticals' Change in Account Payables stood at $1.4 million in 2022, then soared by 605.19% to $10.2 million in 2023, then tumbled by 50.67% to $5.0 million in 2024, then sank by 58.13% to $2.1 million in 2025, then slumped by 292.36% to -$4.1 million in 2026.
• Business Quant data shows CPRX's Change in Account Payables at -$4.1 million in Q1 2026, $2.1 million in Q4 2025, and $3.6 million in Q3 2025.